Orchard Therapeutics plc
Orchard Therapeutics plc (ORTX): 9 pipeline candidates · ~8 mo cash runway · 5 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
7.9 months
D/E 1.52 · 100391% dilution
Lead: Approved
9 candidates
N/A
N/A
A transparent, data-derived signal for Orchard Therapeutics plcacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$23.5M
Quarterly Burn
$23.9M
Runway
7.9 mo
Revenue
$6.3M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (9 candidates)
| Drug | Phase |
|---|---|
| experimental | Phase 3 |
| libmeldy | Approved |
| otl-104 | Phase 3 |
| otl-105 | Phase 3 |
| otl-200 | Phase 2 |
| otl-200 gene therapy | Phase 1/Phase 2 |
| otl-201 | Phase 3 |
| otl-203 | Phase 3 |
| otl-204 | Phase 3 |
Frequently asked questions
How many drug candidates are in Orchard Therapeutics plc's pipeline?
Orchard Therapeutics plc (ORTX) has 9 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Orchard Therapeutics plc's lead drug candidate?
Orchard Therapeutics plc's most advanced tracked candidate is experimental (Phase 3).
What is Orchard Therapeutics plc's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Orchard Therapeutics plc has approximately 7.9 months of cash runway.
Who is the CEO of Orchard Therapeutics plc?
Health Affairs is the chief executive officer of Orchard Therapeutics plc (ORTX).
Get the full picture on Orchard Therapeutics plc
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.